Reducing CVD risk in type 2 DM.
McCall
Anthony L
AL
Department of Internal Medicine, UVA Health System, Charlottesville, VA 22908, USA. alm3j@virginia.edu
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage; D001521:Behavior Therapy; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003925:Diabetic Angiopathies / Q000517:prevention & control; D004040:Dietary Carbohydrates / Q000008:administration & dosage; D004041:Dietary Fats / Q000008:administration & dosage; D015444:Exercise; D006801:Humans; D007336:Insulin, Isophane / Q000008:administration & dosage; D019808:Losartan / Q000008:administration & dosage; D012307:Risk Factors; D016540:Smoking Cessation
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D004040:Dietary Carbohydrates; D004041:Dietary Fats; D007336:Insulin, Isophane; D019808:Losartan; D001241:Aspirin